The results showed that, for glioma, the RBPS scores were positively correlated with the expression of immune checkpoint molecules, PDCD1, CD274, PDCD1LG2, CTLA4, CD86, CD80, CD276, and FAS (Spearman, BH-adjusted p < 0.05) but negatively correlated with VTCN1 (Spearman, BH-adjusted p < 0.05; Figure 4C). This evidence concerns the gene PDCD1LG2 and central nervous system cancer.